3/25
08:00 am
bntc
Benitec Biopharma Inc. Announces Pricing of $30 Million Common Stock Offering
Medium
Report
Benitec Biopharma Inc. Announces Pricing of $30 Million Common Stock Offering
3/24
08:09 am
bntc
Benitec Biopharma Inc. (NASDAQ: BNTC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $28.00 price target on the stock.
High
Report
Benitec Biopharma Inc. (NASDAQ: BNTC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $28.00 price target on the stock.
3/19
07:00 am
bntc
Benitec Biopharma Reports Positive Interim Clinical Results for Three Subjects Treated with BB-301 in Phase 1b/2a Study to be Presented at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
Low
Report
Benitec Biopharma Reports Positive Interim Clinical Results for Three Subjects Treated with BB-301 in Phase 1b/2a Study to be Presented at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
3/10
07:15 am
bntc
Benitec Biopharma (NASDAQ:BNTC) Is In A Good Position To Deliver On Growth Plans [Yahoo! Finance]
Medium
Report
Benitec Biopharma (NASDAQ:BNTC) Is In A Good Position To Deliver On Growth Plans [Yahoo! Finance]
2/26
07:00 am
bntc
Benitec Biopharma to Participate in Upcoming Conferences in March
Medium
Report
Benitec Biopharma to Participate in Upcoming Conferences in March
2/21
08:13 am
bntc
Benitec Biopharma Inc. (NASDAQ: BNTC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $28.00 price target on the stock.
Medium
Report
Benitec Biopharma Inc. (NASDAQ: BNTC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $28.00 price target on the stock.
2/20
07:17 pm
bntc
Benitec Biopharma (BNTC) is on the Move, Here's Why the Trend Could be Sustainable [Yahoo! Finance]
Medium
Report
Benitec Biopharma (BNTC) is on the Move, Here's Why the Trend Could be Sustainable [Yahoo! Finance]
2/14
09:15 am
bntc
Benitec Biopharma Announces Acceptance of Late- Breaking Oral Abstract for the BB-301 Phase 1b/2a Clinical Study at the Muscular Dystrophy Association Clinical and Scientific Conference [Yahoo! Finance]
Medium
Report
Benitec Biopharma Announces Acceptance of Late- Breaking Oral Abstract for the BB-301 Phase 1b/2a Clinical Study at the Muscular Dystrophy Association Clinical and Scientific Conference [Yahoo! Finance]
2/14
09:15 am
bntc
Benitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational Update [Yahoo! Finance]
Medium
Report
Benitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational Update [Yahoo! Finance]
2/14
08:10 am
bntc
Benitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational Update
High
Report
Benitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational Update
2/14
08:00 am
bntc
Benitec Biopharma Announces Acceptance of Late- Breaking Oral Abstract for the BB-301 Phase 1b/2a Clinical Study at the Muscular Dystrophy Association Clinical and Scientific Conference
High
Report
Benitec Biopharma Announces Acceptance of Late- Breaking Oral Abstract for the BB-301 Phase 1b/2a Clinical Study at the Muscular Dystrophy Association Clinical and Scientific Conference
1/27
08:00 am
bntc
Benitec Biopharma to Participate in Upcoming Conferences in January and February
Low
Report
Benitec Biopharma to Participate in Upcoming Conferences in January and February